immun
signatur
measur
baselin
immedi
prior
vaccin
may
predict
immun
respons
vaccin
prevaccin
assess
might
allow
populationbas
also
person
vaccin
strategi
precis
vaccin
baselin
immun
signatur
predict
underli
mechan
reflect
may
also
determin
vaccin
outcom
thu
baselin
signatur
might
contribut
identifi
intervent
target
modul
prior
vaccin
order
improv
vaccin
respons
concept
potenti
transform
vaccin
strategi
usher
new
approach
improv
global
health
captur
baselin
via
system
immunolog
vaccin
prevent
infect
diseas
among
effect
lifesav
medic
intervent
histori
past
vaccin
design
larg
empir
howev
approach
thu
far
mostli
fail
tackl
complex
infect
hiv
mycobacterium
tuberculosi
tb
plasmodium
sp
malaria
well
cancer
noncommunic
diseas
failur
attribut
lack
insight
underli
mechan
vaccin
induc
protect
ie
rule
immun
recent
technolog
advanc
includ
highli
multiplex
immun
profil
datadriven
comput
model
rais
prospect
identifi
rule
global
applic
system
biolog
vaccin
system
vaccinolog
see
glossari
involv
assess
molecular
cellular
state
immun
system
vaccin
comprehens
unbias
multiom
manner
omic
use
develop
datadriven
model
predict
postvaccin
pathogenspecif
immun
respons
eg
antigenspecif
antibodi
titer
goal
identifi
key
molecular
immun
paramet
correl
potenti
shape
vaccin
respons
approach
alreadi
led
new
insight
instanc
correl
earli
postvaccin
host
respons
outcom
eg
antibodi
respons
rais
hypothesi
microbiom
may
involv
vaccin
respons
antibioticinduc
shift
microbiom
influenc
respons
influenza
viru
vaccin
mice
potenti
human
unbias
system
approach
increasingli
appli
vaccin
design
test
also
led
increas
appreci
extens
baselin
respons
variabl
mani
immun
paramet
among
individu
within
popul
given
pervas
popul
heterogen
abl
predict
might
respond
given
vaccin
necessari
moreov
understand
immun
statu
prior
vaccin
shape
vaccin
respons
import
recent
thought
possibl
human
influenza
viru
hepat
b
viru
hbv
malaria
vaccin
specif
aim
would
assess
whether
subject
immun
statu
prior
vaccin
allow
predict
respons
ie
concept
baselin
predict
outcom
extens
baselin
variabl
immun
respons
eg
antibodi
titer
among
individu
given
popul
increasingli
appreci
major
contributor
vaccin
respons
heterogen
concept
baselin
may
predict
outcom
recent
report
human
influenza
viru
yellow
fever
viru
hepat
b
viru
well
malaria
vaccin
concept
might
also
appli
vaccin
abil
predict
might
respond
immun
extent
might
offer
avenu
optim
current
vaccin
strategi
posit
simpl
concept
might
use
signific
vaccin
design
baselin
determin
outcom
alter
baselin
prior
vaccin
could
alter
outcom
approach
could
potenti
lead
tailor
precis
vaccin
ensur
major
individu
vaccin
respond
elicit
protect
immun
respons
ie
devoid
nonrespond
individu
presum
approach
might
also
allow
administr
fewer
vaccin
dose
potenti
arriv
one
vaccin
dose
multiscal
system
biolog
section
laboratori
immun
system
biolog
niaid
center
human
immunolog
chi
nih
bethesda
md
usa
import
assumpt
implic
embodi
hypothesi
baselin
determin
outcom
alter
baselin
vaccin
might
potenti
alter
outcom
evid
albeit
indirect
preliminari
support
hypothesi
purpos
opinion
highlight
potenti
paradigm
one
reshap
baselin
immun
statu
optim
vaccin
respons
might
allow
design
vaccin
strategi
lead
effect
safe
protect
immun
respons
ie
elimin
nonrespond
vaccine
may
also
enabl
strategi
allow
administr
fewer
vaccin
dose
ideal
one
dose
box
furthermor
mani
licens
intervent
eg
drug
adjuv
biolog
known
immunomodulatori
function
might
potenti
repurpos
modifi
baselin
statu
target
fashion
addit
tool
advanc
allow
test
paradigm
human
includ
singlecel
largescal
immun
profil
comput
model
approach
may
contribut
determin
exampl
immun
baselin
modul
administ
tailor
fashion
type
vaccin
review
evid
support
notion
baselin
immun
statu
predict
potenti
impact
vaccin
respons
hypothes
iter
applic
populationbas
system
vaccinolog
studi
follow
administr
immun
modul
vaccin
help
deciph
baselin
immun
statu
might
impact
vaccin
outcom
identif
predict
paramet
rule
import
step
toward
reach
ultim
goal
abil
predict
vaccin
outcom
prior
administr
along
tailor
vaccin
design
protect
one
hundr
year
ago
influenza
viru
pandem
emerg
new
influenza
viru
infect
onethird
world
popul
kill
million
peopl
within
year
put
perspect
pandem
kill
peopl
month
aid
last
year
today
influenza
viru
infect
still
loom
one
greatest
public
health
threat
great
advanc
made
understand
influenza
viru
progress
slow
understand
human
immun
system
prevent
control
influenza
viru
infect
develop
better
vaccin
result
current
influenza
viru
vaccin
moder
effect
blunt
annual
epidem
would
offer
limit
protect
global
pandem
due
novel
influenza
viral
strain
respons
influenza
viru
vaccin
highli
variabl
across
given
popul
leav
individu
without
protect
even
season
vaccin
match
circul
influenza
viral
strain
chang
antibodi
titer
influenza
viru
follow
vaccin
reason
correl
protect
cop
associ
intrins
factor
age
sex
preexist
antibodi
titer
prior
vaccin
histori
howev
much
varianc
antibodi
respons
influenza
viru
vaccin
remain
unexplain
base
studi
twin
genet
seem
contribut
margin
heterogen
vaccin
outcom
adult
suggest
environment
factor
key
driver
concept
baselin
may
predict
outcom
lend
precis
public
health
ie
popul
level
alreadi
done
influenza
viru
vaccin
everi
year
differ
vaccin
influenza
viru
andor
differ
number
dose
vaccin
administ
depend
age
individu
prior
vaccin
statu
exampl
child
might
receiv
one
dose
previous
vaccin
two
dose
vaccin
either
quadrival
intranas
liveattenu
vaccin
inactiv
vaccin
wherea
individu
age
year
might
receiv
singl
dose
standard
quadrival
inactiv
vaccin
highdos
vaccin
formul
includ
adjuv
trend
immunolog
earli
systemsbiolog
analys
influenza
viru
vaccin
identifi
antibodi
respons
predictor
base
postvaccin
paramet
magnitud
plasmablast
increas
day
chang
blood
hostderiv
transcript
day
vaccin
observ
rais
question
whether
baselin
determin
postvaccin
paramet
might
exist
ultim
shape
qualiti
quantiti
antibodi
respons
follow
vaccin
search
root
predictor
season
pandem
viral
strain
consid
framework
transform
multimod
data
set
natur
popul
variat
comput
model
design
predict
serolog
respons
influenza
viru
vaccin
use
baselin
data
alon
independ
age
sex
initi
serolog
antigen
specif
b
cell
popul
vaccin
antigen
high
versu
low
human
respond
could
robustli
predict
essenti
paramet
contribut
predict
compris
frequenc
circul
immun
cell
subset
especi
b
cell
subpopul
among
tempor
stabl
within
subject
period
month
howev
immun
cell
subpopul
paramet
also
highest
betweensubject
variat
thu
like
predict
delin
distinct
baselin
immun
state
among
individu
baselin
biomark
robustli
valid
particularli
attract
might
potenti
provid
relev
inform
time
measur
occur
addit
evid
exist
baselin
predictor
influenza
viru
vaccin
respons
came
addit
studi
peripheralblood
helper
cell
count
classswitch
memori
b
cell
frequenc
time
vaccin
correl
antibodi
respons
annual
trival
inactiv
influenza
vaccin
tiv
also
follow
vaccin
recent
multipl
influenza
viru
vaccin
cohort
span
distinct
annual
season
human
immunolog
project
consortium
hipc
nation
institut
health
nih
center
human
immunolog
chi
geograph
locat
locat
north
america
leverag
identifi
baselin
transcript
predict
signatur
antibodi
respons
influenza
viru
vaccin
analysi
reveal
baselin
predict
signatur
younger
year
age
individu
similar
observ
previous
identifi
baselin
predict
signatur
togeth
signatur
emerg
multipl
omic
approach
eg
cell
popul
analys
plu
transcriptom
could
potenti
captur
inher
biolog
state
individu
vaccin
comprehens
influenza
viru
prevaccin
hostspecif
predict
signatur
exist
beyond
reflect
intrins
variabl
age
sex
predictor
like
reflect
cumul
effect
environ
addit
potenti
past
exposur
influenza
viru
howev
preexist
frequenc
antigenspecif
b
cell
blood
often
associ
antibodi
respons
influenza
viru
vaccin
suggest
known
baselin
predict
signatur
may
independ
antigenspecif
immun
assess
signatur
search
addit
predictor
divers
popul
essenti
help
guid
develop
nextgener
vaccin
provid
persist
immun
influenza
viral
strain
especi
pandem
scenario
box
glossari
cellular
index
transcriptom
epitop
sequenc
citeseq
analyz
singlecel
level
gene
express
profil
cell
via
mrna
protein
amount
checkpoint
immunotherapi
target
immun
checkpoint
molecul
aim
enabl
immun
cell
attack
malign
cell
case
cancer
classswitch
b
cell
b
cell
rearrang
genet
inform
ceas
produc
surfac
igm
antibodi
secret
class
antibodi
igg
iga
etc
imiquimod
use
therapi
treat
exampl
wart
superfici
basal
cell
carcinoma
actin
keratosi
believ
act
modul
local
immun
environ
intrins
versu
extrins
variabl
age
sex
genet
intrins
variabl
factor
microbiom
past
exposur
includ
previou
vaccin
infect
extrins
variabl
squalen
natur
oil
compound
made
eg
skin
adjuv
ad
vaccin
increas
immun
respons
eg
antibodi
titer
system
vaccinolog
approach
system
biolog
ie
highli
multiplex
immun
profil
datadriven
comput
model
appli
studi
vaccin
respons
hipcchi
multicohort
metaanalysi
influenza
viru
vaccin
discuss
put
baselin
predictor
older
individu
found
although
valid
independ
cohort
signatur
distinct
young
individu
specif
baselin
paramet
posit
correl
antibodi
respons
young
year
age
tend
neg
correl
antibodi
respons
older
individu
year
age
underli
mechan
remain
unclear
observ
emerg
data
across
sever
vaccin
season
suggest
young
older
adult
might
inde
share
baselin
predict
paramet
effect
vaccin
outcom
could
age
depend
approxim
world
popul
ie
billion
person
serolog
evid
hbv
infect
year
approxim
hbvinfect
person
die
chronic
liver
diseas
world
health
organ
recommend
univers
neonatalinf
hbv
immun
well
vaccin
adult
risk
hbv
infect
current
hbv
vaccin
compris
hepat
b
surfac
antigen
hb
employ
twoto
fourdos
vaccin
schedul
serolog
cop
chronic
hbv
infect
one
best
defin
vaccin
constitut
titer
miuml
antihb
antibodi
defin
antihb
refer
prepar
direct
correl
quantit
antibodi
titer
protect
individu
achiev
antihb
respons
miuml
one
two
dose
vaccin
specif
one
dose
two
dose
unfortun
persist
nonrespond
vaccin
popul
stay
unprotect
even
complet
vaccin
schedul
similar
influenza
viru
vaccin
cell
popul
transcript
paramet
measur
baselin
ie
prior
vaccin
might
predict
hbv
vaccin
respons
outcom
specif
adult
age
year
higher
express
inflammatori
respons
transcript
increas
frequenc
proinflammatori
innat
immun
cell
peripher
blood
correl
lower
antihb
antibodi
respons
also
case
younger
adult
year
nonrespond
show
activ
state
immun
vaccin
respond
determin
increas
express
granulin
precursor
gene
grn
higher
granulocyt
number
peripher
blood
nonrespond
young
individu
rel
respond
thu
might
possibl
defin
baselin
predict
signatur
subject
gener
protect
respons
follow
hbv
vaccin
malaria
remain
major
global
health
problem
caus
plasmodium
sp
infect
caus
estim
million
case
death
alon
decad
research
thu
far
result
singl
licens
subunit
vaccin
candid
rt
compound
despit
recommend
pilot
implement
studi
ongo
africa
sinc
april
efficaci
vaccin
clinic
malaria
best
moder
limit
durat
present
unknown
rt
vaccin
protect
proport
immun
subject
specif
year
booster
dose
year
vaccin
base
liveattenu
plasmodium
falciparum
parasit
irradi
chemoprophylaxi
antimalari
agent
promis
altern
shown
efficaci
small
clinic
trial
adult
major
knowledg
gap
develop
effect
malaria
vaccin
absenc
immun
cop
understand
specif
mechan
protect
immun
best
correl
either
malaria
vaccin
titer
igg
antibodi
main
vaccin
antigen
circumsporozit
protein
csp
thought
prevent
liverstag
infect
thu
subsequ
bloodstag
infect
caus
clinic
diseas
howev
unlik
antihb
antibodi
titer
follow
hbv
vaccin
posit
predict
valu
vaccineinduc
igg
titer
low
consid
cop
relev
concept
determin
immun
baselin
time
vaccin
predict
vaccin
outcom
peripher
blood
monocytetolymphocyt
ratio
baselin
neg
correl
rt
efficaci
complet
larg
phase
random
prevent
clinic
trial
african
children
primari
outcom
frequenc
first
case
malaria
meet
primari
case
definit
suggest
baselin
proport
white
blood
cell
might
consid
predict
paramet
assess
respons
rt
vaccin
priori
recent
studi
deriv
tengen
blood
transcript
surrog
tgsig
tempor
stabl
cell
frequencybas
baselin
signatur
predict
antibodi
respons
influenza
viru
vaccin
nih
cohort
highlight
earlier
author
show
peripher
blood
mrna
express
tgsig
predict
influenza
viru
vaccin
respons
three
four
independ
us
locat
four
differ
vaccin
season
gene
express
tgsig
also
predict
antibodi
respons
yellow
fever
yf
vaccin
liveattenu
viru
given
individu
support
notion
particular
baselin
signatur
might
captur
predict
inform
beyond
antigenspecif
prior
exposur
studi
author
use
simultan
protein
transcriptom
analysi
cellular
index
transcriptom
epitop
sequenc
citeseq
singl
peripher
blood
mononuclear
cell
high
low
influenza
viru
vaccin
respond
differenti
base
antibodi
titer
produc
respons
influenza
vaccin
result
reveal
complex
network
tgsig
express
correl
cell
cycl
activ
type
ifn
respons
statu
cellular
circuit
compris
plasmacytoid
dendrit
cell
pdc
classswitch
b
cell
lymphocyt
interact
circuit
cell
known
fulli
activ
immun
challeng
infect
yet
healthi
high
vaccin
respond
display
elev
activ
statu
baselin
mechan
maintain
activ
state
restrain
fullblown
system
respons
vaccin
inflammatori
stimul
remain
determin
howev
result
suggest
baselin
predictor
might
share
across
differ
type
vaccin
preexpos
popul
base
aforement
reason
specul
baselin
immun
statu
might
impact
respons
wider
rang
vaccin
howev
largerscal
studi
need
defin
assess
predictor
integr
simultan
assess
genet
microbiom
intrins
factor
age
sex
etc
nongenet
immun
statu
across
differ
vaccin
metaanalysi
immun
profil
data
heterogen
studi
involv
differ
vaccin
popul
power
current
data
modal
share
across
studi
larg
limit
blood
transcript
profil
andor
assess
frequenc
major
circul
immun
cell
popul
thu
robust
target
studi
involv
random
vaccin
trial
individu
without
certain
baselin
immun
signatur
need
delin
extent
baselin
predict
influenc
outcom
differ
type
vaccin
concept
modul
baselin
modul
vaccin
outcom
figur
key
figur
might
empir
realiz
target
modul
immun
statu
baselin
exampl
administr
antibiot
chang
individu
microbiom
frequenc
composit
well
potenti
inflammatori
statu
baselin
eg
perhap
due
underli
patholog
turn
might
impact
antibodi
respons
influenza
viru
vaccin
moreov
vaccin
alter
immun
baselin
statu
thu
also
potenti
outcom
subsequ
vaccin
box
exampl
bacil
bcg
vaccin
one
wide
use
vaccin
worldwid
addit
provid
moder
protect
tb
nonspecif
heterolog
immunomodulatori
effect
beyond
target
pathogen
tb
includ
respons
vaccin
infect
malaria
possibl
even
exampl
bcg
vaccin
associ
increas
antibodi
respons
hbv
polio
viru
type
pneumococcu
sp
influenza
viru
vaccin
underli
mechan
bcg
impact
subsequ
vaccin
fulli
elucid
could
involv
trend
immunolog
shift
respons
immun
cell
cytokin
baselin
cytomegaloviru
cmv
infect
known
affect
multipl
compon
innat
adapt
immun
system
associ
enhanc
immun
respons
higher
antibodi
titer
young
healthi
human
influenza
viru
vaccin
rel
noncmv
infect
subject
howev
observ
older
adult
suggest
impact
cmv
might
age
depend
aspect
certainli
merit
investig
contrast
epsteinbarr
viru
ebv
infect
also
known
affect
multipl
compon
innat
adapt
immun
associ
reduc
respons
lower
antibodi
titer
routin
infant
vaccin
rel
noninfect
subject
import
note
increas
immun
activ
baselin
alway
lead
better
vaccin
respons
like
type
quantiti
cellular
specif
activ
host
factor
age
matter
exampl
activ
immun
state
natur
killer
clinician
corner
although
larg
unexplor
baselin
immun
statu
might
also
predict
clinic
outcom
infecti
diseas
exampl
follow
risk
sever
infect
earli
life
predict
baselin
innat
immun
phenotyp
measur
birth
certain
immun
signatur
baselin
predict
respons
malaria
vaccin
clinic
outcom
acut
infect
ebola
viru
infect
case
fatal
rate
approxim
individu
succumb
diseas
other
recov
even
control
infect
asymptomat
manner
differenti
pathogenesi
ebola
viru
infect
also
due
variat
baselin
immun
statu
could
immunomodul
enhanc
protect
thu
transform
individu
would
otherwis
die
ebola
viru
infect
asymptomat
infect
infect
bellshap
pathogenesi
curv
rang
infect
individu
rapid
progressor
moder
progressor
elit
control
could
baselin
predict
signatur
immun
respons
identifi
lead
novel
prevent
control
measur
concept
limit
infecti
diseas
ongo
revolut
cancer
immunotherapi
use
checkpoint
inhibitor
respons
highli
variabl
across
patient
popul
exampl
less
subject
across
spectrum
cancer
receiv
checkpoint
immunotherapi
benefit
clinic
predict
signatur
could
ideal
identifi
respond
nonrespond
therapi
commenc
vaccin
mean
modul
immun
baselin
suggest
occur
birth
exampl
influenza
viru
vaccin
pregnanc
found
alter
immun
cytokin
product
profil
nasal
mucos
fluid
infant
specif
signific
upregul
downregul
tarc
mdc
document
compar
vaccin
pregnanc
implic
find
infant
vaccin
respons
investig
data
highlight
concept
immunomodul
baselin
prior
vaccin
might
relev
matern
immun
well
trend
trend
immunolog
immunolog
figur
vaccin
could
influenza
viru
vaccin
young
adult
immunomodul
increas
baselin
activ
immun
pathway
blue
broken
line
could
increas
vaccineinduc
immun
respons
vaccin
b
could
hepat
b
viru
vaccin
immunomodul
decreas
baselin
activ
distinct
immun
pathway
blue
broken
line
could
increas
vaccineinduc
antibodi
respons
note
target
baselin
modul
immun
activ
associ
vaccin
respons
could
complet
distinct
simplifi
illustr
meant
indic
chang
induc
baselin
modul
would
occur
particular
cell
pathway
immun
activ
eg
antibodi
cell
respons
nk
cell
proinflammatori
monocyt
differenti
tb
cell
subset
associ
reduc
respons
lower
antibodi
titer
yf
vaccin
prior
vaccin
african
popul
rel
control
moreov
consist
aforement
studi
hbv
vaccin
elderli
pronounc
inflammatori
gene
express
profil
baselin
predict
poorer
respons
vaccin
rel
less
pronounc
inflammatori
gene
express
profil
furthermor
oral
administr
immunosuppress
rapamycin
shown
increas
immun
respons
influenza
viru
vaccin
higher
antibodi
respons
older
adult
rel
receiv
rapamycin
addit
rapamycin
small
molecul
biolog
immunomodulatori
function
imiquimod
current
approv
clinic
use
thu
tool
modul
immun
baselin
statu
potenti
improv
outcom
vaccin
alreadi
avail
posit
base
observ
modul
baselin
tune
vaccin
outcom
vaccineand
populationdepend
manner
possibl
figur
concept
indirectli
support
data
sever
infecti
diseas
differ
host
baselin
statu
time
infect
may
link
differ
clinic
outcom
mani
baselin
predict
signatur
identifi
far
associ
innat
immun
function
thu
may
reflect
recent
activ
function
interact
cell
prior
time
vaccin
hint
possibl
acut
modul
baselin
immun
statu
long
vaccin
could
alter
outcom
concept
deliber
modul
baselin
improv
outcom
vaccin
howev
never
directli
assess
specif
vaccin
adjuv
administ
simultan
vaccin
enhanc
respons
vaccin
knowledg
optim
time
administr
adjuv
relat
vaccin
antigen
determin
origin
choic
combin
adjuv
antigen
one
administr
obviou
practic
benefit
number
inject
reduc
howev
given
mani
vaccin
requir
multipl
dose
provid
protect
presum
advantag
coadministr
adjuv
antigen
may
small
even
becom
disadvantag
modul
baselin
prior
vaccin
ultim
reduc
number
vaccin
dose
administ
begin
assess
approach
experiment
one
could
administ
specif
approv
agent
discuss
earlier
rapamycin
vaccin
bcg
even
alter
specif
compon
microbiom
prior
administr
vaccin
assess
vaccin
outcom
might
also
possibl
determin
whether
better
vaccin
respons
elicit
adjuv
administ
separ
antigen
term
time
vaccin
andor
space
separ
rout
site
administr
obvious
also
import
assess
safeti
reactogen
adjuv
given
alon
note
approach
may
even
requir
chang
exist
vaccin
formul
rather
addit
immunomodul
prior
administr
exist
vaccineadjuv
formul
extens
work
need
test
valid
concept
baselin
predictor
feasibl
util
target
modul
immun
baselin
vaccin
mani
question
remain
see
outstand
question
futur
studi
compar
effect
administr
immunomodul
time
administr
modul
ie
defin
gap
administr
modul
includ
adjuv
vaccin
tempor
stabil
modul
baselin
state
ideal
lead
effect
strategi
develop
better
vaccin
posit
strategi
merit
attent
particularli
consid
vulner
popul
baselin
signatur
reflect
causal
mechan
mere
repres
correl
yettobedetermin
factor
biolog
network
predict
baselin
signatur
similar
distinct
across
differ
popul
eg
young
elderli
pregnant
differ
ethnic
long
variou
baselin
state
last
robust
perturb
infect
shift
microbiom
could
separ
administr
adjuv
antigen
vs
current
standard
coadministr
potenti
vaccin
respons
could
approach
lead
protect
onedos
vaccin
regimen
trend
immunolog
includ
infant
elderli
immunosuppress
individu
well
live
lowand
middleincom
countri
